Skip to main content

Table 3 Analyses of risk factors for poor clinical outcomes in all patients (n = 84)

From: Co-infection with hepatitis B virus among tuberculosis patients is associated with poor outcomes during anti-tuberculosis treatment

Factors

Univariate analysis

Multivariate analysis

OR

95%CI

P-value

OR

95%CI

P-value

Age > 50

3.221

1.19, 8.70

0.021

2.859

3.346

0.93, 8.78

1.15, 9.73

0.067

0.027

Male

2.130

0.55, 8.21

0.272

–

–

–

Alcohol intake > 40 g/d

4.059

0.48, 33.94

0.196

4.199

5.219

0.44, 39.73

0.58, 46.68

0.211

0.139

INH + RFP

0.739

0.26, 2.14

0.740

–

–

–

Latency < 1 month

0.506

0.15, 1.70

0.270

–

–

–

Hepatocellular DILI

1.308

0.47, 3.66

0.609

–

–

–

Cirrhosis

7.588

2.57, 22.37

0.000

4.382

1.35, 14.21

0.014

HBV co-infection

7.333

1.58, 34.10

0.011

4.504

8.012

0.84, 24.05

1.66, 38.66

0.078

0.010

  1. Only variables with P < 0.200 in the univariate analysis were included in the multivariate analysis. Adjusted statistical data were shown in italic font if the variable of cirrhosis was discarded due to its correlation with chronic HBV infection
  2. Abbreviations: INH isoniazid, RFP rifampin, DILI drug-induced liver injury, HBV hepatitis B virus
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us